Drug Type Trispecific antibody |
Synonyms |
Target |
Mechanism FZD4 agonists(frizzled class receptor 4 agonists), IL-6 inhibitors(Interleukin-6 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Preclinical | US | 01 Nov 2024 | |
Uveitic Macular Edema | Preclinical | US | 01 Nov 2024 | |
Wet age-related macular degeneration | Preclinical | US | 01 Nov 2024 |